Lung transplantation is the most effective therapy for patients with end-stage lung disease.
However, concern of donor lung damage and ischemia-reperfusion induced lung injury …

While allograft rejection (AR) continues to threaten the success of cardiothoracic
transplantation, lack of accurate and repeatable surveillance tools to diagnose AR is a major …

Background Chronic lung allograft dysfunction (CLAD), the physiologic correlate of chronic
rejection, remains a major barrier to long-term survival following lung transplant. Biomarkers …

Respiratory viral infection (RVI) in lung transplant recipients (LTRs) is a risk for chronic lung
allograft dysfunction (CLAD). We hypothesize that donor-derived cell-free DNA …

Plasma donor‐derived cell‐free DNA (dd‐cfDNA) is a sensitive biomarker for the diagnosis
of acute rejection in lung transplant recipients; however, differences in dd‐cfDNA levels …

Background. Lung transplant patients are vulnerable to various forms of allograft injury,
whether from acute rejection (AR)(encompassing acute cellular rejection [ACR] and …

Background Many studies have reported the relevance of donor-derived cfDNA (dd-cfDNA)
after lung transplantation (LTx) to diagnose and monitor acute rejection (AR) or chronic …

Rationale: Chronic lung allograft dysfunction (CLAD) results in significant morbidity after
lung transplantation. Potential CLAD occurs when lung function declines to 80–90% of …

Rationale: The association of acute cellular rejection (ACR) with chronic lung allograft
dysfunction (CLAD) in lung transplant recipients has primarily been described before …

Abstract Purpose of Review Acute allograft rejection is a common cause of morbidity and
mortality in heart and lung transplantation. Unfortunately, the current monitoring gold …